Jack Scannell studies biomedical R&D productivity from both an economic and a scientific perspective, particularly the unpalatable contrast between cheaper and better scientific inputs, and what has been a long-term decline in innovative output efficiency. He works as an independent consultant to financial institutions, drug companies, and the public sector.
He is an associate fellow at the Centre for the Advancement of Sustainable Medical Innovation (CASMI) at Oxford University and an honorary fellow in the School of Social and Political Sciences at Edinburgh University. Scannell was head of Discovery Research at e-Therapeutics PLC, an Oxford-based biotechnology firm, applying bioinformatics methods to drug discovery. Prior to that, he worked in drug industry investment, leading the European health care team at Sanford Bernstein from 2005 to 2012. From 1999 to 2005, Scannell worked at the Boston Consulting Group with health care and financial clients. He has a Ph.D. in physiology (computational neuroscience) from Oxford University and a degree in medical sciences from Cambridge University.